carbamates has been researched along with Exanthema in 10 studies
Exanthema: Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To report successful desensitization to amprenavir after the occurrence of a maculopapular exanthem in an HIV-infected patient with late-stage disease and limited antiretroviral treatment options." | 7.73 | Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus. ( Huynh, P; Kohli-Pamnani, A; Lobo, F, 2006) |
| "To report successful desensitization to amprenavir after the occurrence of a maculopapular exanthem in an HIV-infected patient with late-stage disease and limited antiretroviral treatment options." | 3.73 | Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus. ( Huynh, P; Kohli-Pamnani, A; Lobo, F, 2006) |
| " Safety was monitored as clinical adverse events (AEs) and laboratory abnormalities." | 2.70 | Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. ( Lloyd, PP; Lou, Y; Piliero, PJ; Preston, SL; Sadler, BM; Stein, DS, 2001) |
| "Amprenavir (APV) is a new HIV-I protease inhibitor used in combination with other antiretroviral agents for the treatment of HIV-1 infection." | 2.69 | Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection. ( Brothers, C; Fetter, A; Millard, J; Pagano, G; Pedneault, L; Tymkewycz, P; Yeo, J, 2000) |
| "Fosamprenavir is a protease inhibitor (PI) approved for the treatment of HIV-1 infection." | 2.44 | Fosamprenavir calcium plus ritonavir for HIV infection. ( Arduino, RC; Torres, HA, 2007) |
| " We evaluated dosage and serum levels, efficacy, drug interactions, and adverse effects." | 1.72 | Initial Real-World Experience With Cenobamate in Adolescents and Adults: A Single Center Experience. ( Elliott, T; Gienapp, AJ; Ridley-Pryor, T; Wheless, JW, 2022) |
| "Encorafenib is a BRAF inhibitor increasingly used as a second-line treatment for metastatic melanoma and colorectal cancer." | 1.72 | Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases. ( Alfallouji, Y; Borysiewicz, C; Bunker, CB; Calonje, E; Hodgkinson, T; Perrett, CM; Sidwell, RU; Spencer, A; Wasan, H; Watchorn, R, 2022) |
| "The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies." | 1.46 | Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study. ( Chae, HB; Cho, BW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Lee, BS; Lee, SH; Lee, TH; Song, IH, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elliott, T | 1 |
| Ridley-Pryor, T | 1 |
| Gienapp, AJ | 1 |
| Wheless, JW | 1 |
| Alfallouji, Y | 1 |
| Spencer, A | 1 |
| Calonje, E | 1 |
| Perrett, CM | 1 |
| Watchorn, R | 1 |
| Borysiewicz, C | 1 |
| Hodgkinson, T | 1 |
| Wasan, H | 1 |
| Bunker, CB | 1 |
| Sidwell, RU | 1 |
| Sankhyan, P | 1 |
| Gonzalez-Estrada, A | 1 |
| Cho, BW | 1 |
| Kim, SB | 1 |
| Song, IH | 1 |
| Lee, SH | 1 |
| Kim, HS | 1 |
| Lee, TH | 1 |
| Kang, YW | 1 |
| Kim, SH | 1 |
| Lee, BS | 1 |
| Chae, HB | 1 |
| Rojas, P | 1 |
| Sánchez, L | 1 |
| Santos, A | 1 |
| Góõmez, MP | 1 |
| Blanco, H | 1 |
| Laguna, JJ | 1 |
| Kohli-Pamnani, A | 1 |
| Huynh, P | 1 |
| Lobo, F | 1 |
| Torres, HA | 1 |
| Arduino, RC | 1 |
| Pedneault, L | 1 |
| Brothers, C | 1 |
| Pagano, G | 1 |
| Tymkewycz, P | 1 |
| Yeo, J | 1 |
| Millard, J | 1 |
| Fetter, A | 1 |
| Sadler, BM | 1 |
| Piliero, PJ | 1 |
| Preston, SL | 1 |
| Lloyd, PP | 1 |
| Lou, Y | 1 |
| Stein, DS | 1 |
1 review available for carbamates and Exanthema
| Article | Year |
|---|---|
Fosamprenavir calcium plus ritonavir for HIV infection.
Topics: Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Exanthema; | 2007 |
2 trials available for carbamates and Exanthema
| Article | Year |
|---|---|
Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection.
Topics: Adolescent; Adult; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Digestive System; Drug Ther | 2000 |
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.
Topics: Administration, Oral; Adult; Body Mass Index; Carbamates; Diarrhea; Dose-Response Relationship, Drug | 2001 |
7 other studies available for carbamates and Exanthema
| Article | Year |
|---|---|
Initial Real-World Experience With Cenobamate in Adolescents and Adults: A Single Center Experience.
Topics: Adolescent; Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug-Related Side Effec | 2022 |
Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Exanthema; Humans; Mu | 2022 |
Mixed Essential Cryoglobulinemia.
Topics: Antiviral Agents; Carbamates; Cryoglobulinemia; Exanthema; Hepatitis C; Heterocyclic Compounds, 4 or | 2017 |
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Dru | 2017 |
Hypersensitivity to repaglinide.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Erythema; Exanthema; Hum | 2011 |
Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus.
Topics: Adult; Carbamates; Desensitization, Immunologic; Drug Hypersensitivity; Exanthema; Female; Furans; H | 2006 |
Amprenavir: a new HIV protease inhibitor.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Carbamates; Child; Clinical Trials as Topi | 1999 |